News & Events

Keep up with UF Innovate | Tech Licensing

Read the latest news about UF startups, Tech Licensing, startup companies, programs and events below. If you’d like to have this news delivered via social media or email:

Startups in the News

  • ViewRay Picks up Ex-Spectranetics CEO Drake, COO Matin | Personnel Moves (Mass Device)
    UF startup ViewRay said it tapped former Spectranetics head Scott Drake as its new chief executive officer and former Spectranetics COO Shar Matin as its new COO. Before joining ViewRay, Drake served as CEO and prez of Spectranetics, which was acquired by Royal Philips in a deal that closed last August. Drake also serves as board chair for AtriCure and JustRight Surgical. Newly appointed COO Matin also worked for Spectranetics, starting in 2007, and holding the COO position from 2014 until it was acquired by Philips.... Read more »
  • New Diagnostic Blood Test Developed for Concussions (eHealth News)
    UF biotech company, Banyan Biomarkers, Inc. has developed the first blood test that can be used by physicians to objectively aid in the evaluation of patients with suspected traumatic brain injury (TBI) or concussions. The Banyan Brain Trauma Indicator® (Banyan BTI) consists of two diagnostic test kits, Banyan UCH-L1® Kit and Banyan GFAP® Kit, which measure two specific protein biomarkers that rapidly appear in the blood after a brain injury. According to the developers, the Banyan BTI can be used to rule out the need for a head CT scan in patients 18 years of age and older with a suspected TBI.... Read more »
  • Sun Biopharma, Inc. Presents Poster at Pancreasfest in Pittsburgh, Pa. (Globe Newswire)
    UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic diseases, announced the presentation of a poster reviewing the results of the Phase 1 Safety Study of its candidate drug, SBP-101, a polyamine metabolic inhibitor for pancreatic ductal adenocarcinoma (PDA) at PancreasFest in Pittsburgh, PA. PancreasFest is an international meeting of physicians and scientists committed to reporting and sharing research in pancreatic cancer and pancreatitis. The poster was presented by Michael Walker, M.D., Director of Pancreatic Research for Sun BioPharma. Dr. Walker said, “The conclusion of the study was that SBP-101 was well tolerated at dose levels 1-4 and that a dose of 0.8 mg/kg of body weight exceeded the maximum tolerated dose (MTD). The best tumor response occurred with 0.2 mg/kg/day. The low incidence of adverse events below the MTD and absence of drug-related bone marrow toxicity or peripheral neuropathy in these heavily pre-treated PDA patients, suggest the potential for SBP-101 as an addition to front-line treatment for PDA and justify a combination study.”... Read more »
  • AxoGen, Inc Common Stock (AXGN) Sets New 1-Year High at $56.85 (Fairfield Current)
    UF startup and Sid Martin Biotech alum AxoGen, Inc reported that its Common Stock (NASDAQ:AXGN) shares hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $56.85 and last traded at $54.90, with a volume of 4762 shares changing hands. The stock had previously closed at $56.60. The company has a quick ratio of 2.81, a current ratio of 3.32 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.90 billion, a PE ratio of -182.10 and a beta of 0.04. ... Read more »
  • Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medi (BioFlorida)
    UF startup and Sid Martin Biotech alum Ology Bioservices, Inc., a biologics contract development and manufacturing organization, and Rafa Laboratories, Ltd., a leading Israeli pharmaceutical company, announced that on July 9, 2018, they received full approval from the U.S. Food and Drug Administration (FDA) for the Atropine Injection, 2mg/0.7mL, Single-Dose Autoinjector. The Atropine Autoinjector initially received Emergency Use Authorization from the FDA in April 2017. Atropine is one of the most commonly used drugs for the treatment of chemical nerve agent poisoning. With the approved autoinjector, U.S. troops can rapidly inject atropine into the thigh muscle following nerve agent exposure.... Read more »

Read More in Our Archive…


UF Innovate | Tech Licensing News and Events

Read More in Our Archive…